cp wire

CP Wire Articles

BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced on 5/24/18 that BioMarin received standard approval from the U.S. Food and Drug Administration (FDA) for Palynziq (pegvaliase-pqpz) Injection... read more

Fri, 05/25/18 - 08:45 am
CP Staff

Bicycle Therapeutics, announced on 5/24/18 that it is expanding its collaboration with AstraZeneca to include additional targets in respiratory and cardio-metabolic diseases.

The original... read more

Thu, 05/24/18 - 09:20 am
CP Staff

Brii Bio announced on 5/24/18 its launch with significant partnerships and financing. Brii Bio aims to accelerate the development and delivery of breakthrough medicines in China through... read more

Thu, 05/24/18 - 09:10 am
CP Staff

The test, which is at the proof-of-concept stage, can rapidly screen a drop of blood for biomarkers of pancreatic cancer. It can provide results in less than an hour. The findings were published... read more

Wed, 05/23/18 - 01:06 pm
CP Staff
  • Dr. Bischofberger was at Gilead Sciences for almost 30 years
  • Kronos completed $18 million seed financing
  • The company is advancing two programs built on its small molecule... read more
Wed, 05/23/18 - 09:52 am
CP Staff

Pfizer Inc. (NYSE:PFE) announced on 5/22/18 that tafamidis received Breakthrough Therapy designation from the US Food and Drug Administration (FDA) for the treatment of patients with transthyretin... read more

Wed, 05/23/18 - 09:36 am
CP Staff

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) confirmed on 5/23/18 that the U.S. Food and Drug Administration (FDA) has extended the goal date of the Biologics License Application (BLA... read more

Wed, 05/23/18 - 09:17 am
CP Staff

Ardelyx, Inc. (Nasdaq: ARDX) announced on 5/22/18 the pricing of an underwritten public offering of 12,500,000 shares of its common stock at a public offering price of $4.00 per share, before... read more

Tue, 05/22/18 - 08:57 pm
CP Staff
  • Elayta currently in phase II testing
  • Has been granted fast track status by the FDA
  • Phase I/IIa trials showed Elayta  significantly reduced concentrations of synapse damage... read more
Tue, 05/22/18 - 11:00 am
CP Staff

  • Co-developing drug with Abbvie
  • CytomX is eligible to receive up to $470 million in development, regulatory and commercial milestones
  • CD71 is a highly... read more
Tue, 05/22/18 - 08:41 am
CP Staff

Pfizer Inc. (NYSE:PFE) announced on 5/22/18 that it has started a Phase 1/2 trial of its respiratory syncytial virus (RSV) vaccine candidate in healthy adult volunteers. RSV is a common... read more

Tue, 05/22/18 - 08:30 am
CP Staff

FibroGen, Inc. (NASDAQ:FGEN), announced on 5/21/18 that updated results from the company’s randomized, double-blind, placebo-controlled Phase 2b PRAISE study of pamrevlumab in patients with... read more

Mon, 05/21/18 - 10:44 pm
CP Staff

GRAIL, Inc., announced on 5/21/18 that it has raised USD$300 million in an oversubscribed Series C financing. The financing is led by Ally Bridge Group, co-led by Hillhouse Capital Group and 6... read more

Mon, 05/21/18 - 10:32 pm
CP Staff

Virtually everyone has heard recent discussions about the microbiome and its effect on human health. It... read more
Mon, 05/21/18 - 04:47 pm

Cosmo Pharmaceuticals N.V. (SIX: COPN) announced on 5/21/18 that the U.S. Food and Drug Administration (FDA) has set a PDUFA date of November 16, 2018 for its decision on the New Drug Application... read more

Mon, 05/21/18 - 12:56 pm
CP Staff

ViiV Healthcare, announced on 5/21/18  that the European Commission has granted marketing authorisation for Juluca (dolutegravir 50mg/rilpivirine 25mg) for the treatment of human... read more

Mon, 05/21/18 - 08:30 am
CP Staff

PROCEPT BioRobotics, a Silicon Valley robotics company developing intelligent surgical solutions to transform the field of urology, has announced early data from the global Phase III WATER II (... read more

Mon, 05/21/18 - 08:21 am
CP Staff

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced on 5/18/18 a poster presentation of additional prostate cancer data (Abstract #229675) at the American Society of Clinical Oncology (ASCO)... read more

Fri, 05/18/18 - 09:35 am
CP Staff

Accent Therapeutics, a biopharmaceutical company developing breakthrough treatments for cancer patients, today announced $40 million in Series A capital to establish a discovery platform and... read more

Fri, 05/18/18 - 09:24 am
CP Staff

BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of... read more

Thu, 05/17/18 - 09:53 am
CP Staff


current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.